March 25 (Reuters) - The following statement was released by Pharming (PHAR.AS: Quote, Profile, Research): Biotech company Pharming Group announced today that it has signed an exclusive licensing and distribution agreement with EiP Eczacibasi ilac Pazarlama A.S., a leading Turkish pharmaceutical company for the marketing and sales of Rhucin in Turkey. The agreement covers the use of Rhucin to treat acute attacks of Hereditary Angioedema (HAE) with a right of first refusal to EIP for other indications.
